Ibrutinib: Indication of added benefit in one of three therapeutic indications

Posted by on May 2, 2016 3:12 pm
Categories: health

No added benefit has been proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug.

Leave a Reply

Your email address will not be published. Required fields are marked *